CytomX Therapeutics, Inc.

NasdaqGS:CTMX Stok Raporu

Piyasa değeri: US$82.0m

CytomX Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

CytomX Therapeutics şirketinin toplam hissedar öz sermayesi $-31.2M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $159.2M ve $190.4M dir. CytomX Therapeutics 'in FAVÖK'ü $5.7M faiz karşılama oranı -0.6 dur. Şirketin $137.2M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

0%

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı-0.6x
NakitUS$137.18m
Eşitlik-US$31.23m
Toplam yükümlülüklerUS$190.45m
Toplam varlıklarUS$159.22m

Son finansal sağlık güncellemeleri

Recent updates

Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues

Oct 26
Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues

CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments

Jul 15

The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%

Jun 15
The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%

We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now

May 09
We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now

CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling

May 02

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%

Apr 27
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

Apr 25

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%

Mar 05
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Jan 19
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise

Nov 26
There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise

We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely

Nov 17
We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely

Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts

Mar 29
Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts

Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?

Feb 13
Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?

Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

Nov 10
Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

CytomX Therapeutics to cut workforce by about 40%

Jul 13

CytomX says phase 2 study of breast cancer antibody treatment met main goal

Jul 06

Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Jun 08
Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?

Feb 10
Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?

CytomX: Pullbacks Are Opportunities

Dec 14

CytomX: Solving A Critical Problem In The High-Value ADC Space

Sep 15

We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate

Aug 11
We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CTMX negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: CTMX şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CTMX borçsuzdur.

Borcun Azaltılması: CTMX 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Borç Kapsamı: CTMX un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: CTMX şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.


Bilanço


Sağlıklı şirketleri keşfedin